首页> 外文OA文献 >Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Estrogen Receptor (ER) or Progesterone Receptor (PR) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

【2h】

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Estrogen Receptor (ER) or Progesterone Receptor (PR) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

机译：用于雌激素受体（ER）或孕激素受体（PR）阳性和人表皮生长因子受体2（HER2）阴性乳腺癌的风险分层和预后的新型免疫相关基因签名

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Wei Wang; Hongnan Jiang; Yanrong Gao;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. [J] . Finn RS, Press MF, Dering J Journal of Clinical Oncology . 2009 ,第24期

机译：在紫杉醇联合拉帕替尼或安慰剂作为HER2阴性或未知转移性乳腺癌的一线治疗的随机试验中，雌激素受体，孕激素受体，人表皮生长因子受体2（HER2）和表皮生长因子受体的表达和拉帕替尼的获益。
2. Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：最终分析阶段1对雌激素（RAD1901）的研究，一种新颖的选择性雌激素受体降解剂（SERD），雌激素受体阳性（ER加），人表皮生长因子受体2阴性（HER2-）晚期乳腺癌
3. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. [J] . Parise CA, Bauer KR, Brown MM, The breast journal . 2009 ,第6期

机译：雌激素受体（ER），孕激素受体（PR）和人表皮生长因子受体2（HER2）在加利福尼亚州1999-2004年患有浸润性乳腺癌的女性中定义的乳腺癌亚型。
4. Immunohistochemistry applications in breast carcinoma: The Hypoxia Inducible Factor lα, Estrogen Receptor, Progesterone Receptor and HER2 expression before and after neoadjuvant chemotherapy [C] . Zuofeng Zhang, Yunai Liang, Chunhua Zhang, Technical Congress on Resources, Environment and Engineering . 2016

机译：免疫组织化学在乳腺癌中的应用：缺氧诱导因子Lα，雌激素受体，孕酮受体和Neoadjuvant化疗前后和Her2表达
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. Estrogen Receptor Progesterone Receptor Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer [O] . Richard S. Finn, Michael F. Press, Judy Dering, -1

机译：紫杉醇与拉帕替尼或安慰剂作为HER2阴性或未知转移性乳腺癌的一线治疗的随机试验雌激素受体孕激素受体人表皮生长因子受体2（HER2）和表皮生长因子受体的表达及拉帕替尼的获益
7. Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer [O] . Finn, Richard S., Press, Michael F., Dering, Judy, 2009

机译：紫杉醇与拉帕替尼或安慰剂作为HER2阴性或未知转移性乳腺癌的一线治疗的随机试验，雌激素受体，孕激素受体，人表皮生长因子受体2（HER2）和表皮生长因子受体的表达及拉帕替尼的获益
8. CSrc and Her2 Signaling Pathways Cooperate With Estrogen to Promote Estrogen Receptor Phosphorylation, Ubiquitination and Proteolysis in ER Negative Breast Cancers [R] . Chu, I. 2006

机译：Csrc和Her2信号通路与雌激素合作促进ER阴性乳腺癌中雌激素受体磷酸化，泛素化和蛋白水解

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Estrogen Receptor (ER) or Progesterone Receptor (PR) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

著录项

相似文献

相关主题

期刊订阅